KCT0002524进行中（未招募）未知
A single-blinded, split-face study for comparative evaluation on the efficacy and stability of the treatment of solar lentigo by picosecond Nd:YAG laser(Picocare 450) and traditional nanosecond Q-switched Nd:YAG laser(Pastelle)
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- WONTECH
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 73(Year)（—）
- 性别
- All
入选标准
- •1. Adults younger than 19 and younger than 74
- •2. Those who have three or more photoreactive lentigo larger than 3 mm in diameter on the left and right sides of the face, respectively
- •3. Persons who agreed to take a picture facial
- •4. Persons who agree to and are willing to prohibit the use of topical / systemic steroids (Corticosteroids) or retinoids and topical / systemic skin whitening agents during the course of the trial
- •5. Persons who agree to use the same skin care products in facial area during the clinical trial period and who are willing to comply with them
- •6. I agree to use SPF 50 or more sunscreen every day on facial skin, avoiding excessive sunlight during the clinical trial period, and willingness to adhere to it
- •7. Persons who agree not to undergo other aesthetic procedures, surgery or scarring operations on the face during the clinical trial period
- •8. A woman who has been confirmed as negative in the pregnancy test and has agreed to be contraceptive during the trial period
- •9. Those who voluntarily agree to participate in the clinical trial and are willing to comply with the clinical trial protocol
排除标准
- •1. A person with a history of paralysis due to light
- •2. Those with facial infection, dermatitis, or rash
- •3. Keloid scarring, hypertrophic scarring, Abnormal wound healing history.
- •4. People with vitiligo, eczema, psoriasis
- •5. A person with a history of connective tissue such as systemic lupus erythematosus (Lupus) or scleroderma (Scleroderma)
- •6. Persons with a history of diseases that are stimulated by heat, such as herpes simplex and herpes zoster
- •7. Those who have been receiving radiotherapy or have a history of chemotherapy
- •8. A person with a malignant tumor in the face
- •9. People with a history of allergic reactions to local anesthetics
- •10. Persons who have used bleaching agents (Hydroquinone, Tranexamic acid, etc.), Isotretinoid (or Retinoid), light-sensitive drugs and steroids within the last 6 months
- •11. Those who have received facial cosmetic treatments such as laser, phototherapy, and surgery within the last 6 months or who have received filler treatment with collagen, hyaluronic acid filler or other materials
- •12. Those with heart disease, such as currently unregulated diabetes or resistant hypertension
- •13. Those who are currently taking anticoagulants or have anticoagulation
- •14. Those who have immunocompromised history or are taking immunosuppressive drugs
- •15. A person whose face is excessively tanned
- •16. Pregnant or lactating
- •17. If you have participated in other medical device or drug clinical trials within the last 90 days or are planning to participate in other clinical trials during this trial period
- •18. Any other person who, at the discretion of the examiner, judges of doctor
研究者
相似试验
招募中
Unknown
Clinical Trial of Jelly Containing the Rare Sugar D-Alulose in Patients with Type 2 Diabetes MellitusType 2 diabetesD-alluloseMeSH Unique ID: D003924JPRN-jRCTs061230021Fukunaga Kensaku24
进行中（未招募）
1 期
A Randomized, Single-Blinded, Comparative Study of Mycosinate and Curanail in the Treatment of Fungal Nail InfectioOnychomycosisEUCTR2018-000294-78-IEektr Technologies60
尚未招募
1 期
A comparative interventional study to assess the treatment modalities of atrophic acne scars such as fractional co2 laser and subcisioCTRI/2024/05/066623Belagavi institute of medical sciences
进行中（未招募）
1 期
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002940-26-NLJanssen-Cilag International NV1,270
进行中（未招募）
1 期
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) versus ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerEUCTR2012-002940-26-SKJanssen-Cilag International NV1,270